Wird geladen...
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience
Ibrutinib is an oral Bruton’s tyrosine kinase (BTK) inhibitor, which has recently gained approval by the United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with symptomatic Waldenström macroglobulinemia (WM). Herein, we review...
Gespeichert in:
| Veröffentlicht in: | Ther Adv Hematol |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publications
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959643/ https://ncbi.nlm.nih.gov/pubmed/27493708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716654102 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|